TickerFacts.

NewcelX Ltd. (NCEL): Capital Expenditures

Annual figures by period end, from SEC filings.

$8.0K
Year ended 2025-12-31
$39.6K2021-12-31: $39.6K2023-12-31: $6.0K2024-12-31: $6.0K2025-12-31: $8.0K$8.0K
2021-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$8.0K+33.3%2026-04-29, From 2025-01-01
2024-12-31$6.0K0.0%2026-04-29, From 2024-01-01
2023-12-31$6.0Kn/a2026-04-29, From 2023-01-01
No annual figure between 2021-12-31 and 2023-12-31.
2021-12-31$39.6Kn/a2024-05-15, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
NewcelX Ltd. (NCEL)2025-12-31$8.0K+33.3%
Revelation Biosciences, Inc. (REVB)2024-12-31$19.2Kn/a
MetaVia Inc. (MTVA)2025-12-31$2.0K-75.0%
Decoy Therapeutics Inc. (DCOY)2025-12-31$577.0Kn/a
Lantern Pharma Inc. (LTRN)2025-12-31$1.7K-86.4%
PRF Technologies Ltd. (PRFX)2025-12-31$2.0K-84.6%
Imunon, Inc. (IMNN)2025-12-31$280.6K+849.8%
Traws Pharma, Inc. (TRAW)2025-12-31$2.58M-29.1%
Longeveron Inc. (LGVN)2025-12-31$245.0K-62.6%

Compare NCEL, REVB, MTVA, DCOY side by side · Screen every company in Pharmaceutical Preparations ↗